Advertisement

Picture [iito] No Tracking 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 3041 | Ordered by Date (descending)
1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
SynOx Therapeutics–Forbion: investment, 202011 financing round Series A totalling €37m incl co-investor Forbion 2020-11-19
SynOx Therapeutics–Gimv: investment, 202011 financing round Series A totalling €37m incl co-investor Gimv 2020-11-19
SynOx Therapeutics–Medicxi: investment, 202011 financing round Series A totalling €37m incl co-lead investor Medicxi 2020-11-19
SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap 2020-11-19
SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
Emergex–Consilium: public relations, 202011 service existent by Consilium Strategic Communications 2020-11-18
Emergex–SEVERAL: investment, 202011 financing round $11m from new + existing investors 2020-11-18
Myricx Pharma–Brandon Capital: investment, 202011 seed financing round totalling £4.5m incl investor Brandon Capital Partners 2020-11-16
Myricx Pharma–SEVERAL: investment, 202011 seed financing round £4.5m with Sofinnova Partners + Brandon Capital Partners 2020-11-16
Myricx Pharma–Sofinnova: investment, 202011 seed financing round totalling £4.5m incl investor Sofinnova Partners 2020-11-16
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series 2020-11-09
Congenica–Cambridge Innovation Capital: investment, 202011 financing round Series C totalling £39m incl existing + co-investor CIC 2020-11-09
Congenica–Consilium: public relations, 202011 service existent by Consilium Strategic Communications 2020-11-09
Congenica–Downing Ventures: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Downing 2020-11-09
Congenica–IDO Investments: investment, 202011 financing round Series C totalling £39m incl new + co-investor IDO Investments 2020-11-09
Congenica–Lazard: financial services, 202011 supply service Lazard is financial advisor with regard to £39m Series C financing round 2020-11-09
Congenica–Legal & General: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Legal & General 2020-11-09
Congenica–Parkwalk Advisors: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Parkwalk 2020-11-09
Congenica–Puhua Capital: investment, 202011 financing round Series C totalling £39m incl new + co-investor Puhua Capital 2020-11-09
Congenica–SEVERAL: investment, 202011 financing round Series C £39m ($50m) co-led by Tencent + Legal & General 2020-11-09
Congenica–Tencent: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Tencent 2020-11-09
Congenica–Xeraya: investment, 202011 financing round Series C totalling £39m incl new + co-investor Xeraya 2020-11-09
Oxford Biomedica–PhoreMost: GCT discovery, 202011– collab €na using Siteseeker to find targets for CAR-T cell therapies using LentiVector technology 2020-11-09
Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq 2020-11-05
Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB 2020-11-05
Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB 2020-11-05
VelosBio–Merck (US): investment, 202011– acquisition $2.75b in cash of VelosBio by Merck 2020-11-05
Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd 2020-11-02
Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m 2020-11-02
Horizon Discovery–PerkinElmer: investment, 202011– cash tender offer £296m ($383m) representing total enterprise value of £284m ($368m) 2020-11-02
Mainstay Medical–Fountain Healthcare Partners: investment, 202011 existent investment of Fountain HP Fund III 2020-11-02
Oxford BioDynamics–Instinctif Partners: public relations, 202011 service existent by Instinctif 2020-11-02
Eagle Genomics–ETF Partners: investment, 202010 financing round totalling $9m incl investor Environmental Technologies Fund (ETF) 2020-10-27
Eagle Genomics–Granpool Innovative Investments: investment, 202010 financing round totalling $9m incl investor consortium led by Granpool 2020-10-27
Eagle Genomics–Sarum PR: public relations, 202010 service existent Sarum PR is press contact 2020-10-27
Eagle Genomics–SEVERAL: investment, 202010 financing round $9m with ETF Partners + investor consortium led by Granpool II 2020-10-27
Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor 2020-10-27
Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel 2020-10-27
Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE 2020-10-27
Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) 2020-10-27
Prokarium–Korea Investment Partners: investment, 202010 financing round Series B totalling $21m led by KIP 2020-10-27
Prokarium–Riyadh Valley Company: investment, 202010 financing round Series B totalling $21m incl co-investor RVC (FF) 2020-10-27
Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners 2020-10-27
Prokarium–United Kingdom (govt): investment, 202010 financing round Series B totalling $21m incl co-investor UK Future Fund (FF) 2020-10-27
Unilever–Eagle Genomics: microbiomics, <202010 collab use of e[datascientist] platform to support claims for enzyme-containing Zendium toothpaste 2020-10-27
Base Genomics–Bristows: legal services, 202010 supply Bristows LLP legal advisor to Base Genomics for acquisition by Exact Sciences 2020-10-26
Base Genomics–Exact Sciences: investment, 202010 acquisition 100% of Base Genomics Ltd for $410m in cash (net of cash + certain other adjustments) 2020-10-26
Base Genomics–William Blair: financial services, 202010 supply William Blair financial advisor to Base Genomics for acquisition by Exact Sciences 2020-10-26
Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec 2020-10-26
Exact Sciences–K&L Gates: legal services, 202010 supply legal advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier 2020-10-26
Exact Sciences–XMS Capital: financial services, 202010 supply financial advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier 2020-10-26
Scorpion Therapeutics–Abingworth: investment, 202010 financing round Series A totalling $108m incl co-investor Abingworth 2020-10-26
Scorpion Therapeutics–SEVERAL: investment, 202010 financing round Series A $108m led by Atlas Venture + Omega Funds + Vida Ventures 2020-10-26
Thrive Earlier Detection–Exact Sciences: investment, 202010– acquisition $1.7b upfront with 35% in cash + 65% common stock plus $450m milestones 2020-10-26
Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market 2020-10-19
Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures 2020-10-19
Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BIoMedPartners plus all existing investors 2020-10-19
NovaBiotics–Powerscourt: public relations, 202010 service existent by Powerscourt 2020-10-16
NovaBiotics–United Kingdom (govt): grant, 202010– Innovate UK grant £1m for developm of Nylexa as repurposed therapy for Covid-19 2020-10-16
Oribiotech–Amadeus Capital: investment, 202010 financing round Series A totalling $30m incl existing + co investor Amadeus Capital Partners 2020-10-14
Oribiotech–BAM the Agency: public relations, 202010 service existent by BAM 2020-10-14
Oribiotech–Delin Ventures: investment, 202010 financing round Series A totalling $30m incl existing + co investor Delin Ventures 2020-10-14
Oribiotech–Kindred Capital: investment, 202010 financing round Series A totalling $30m incl existing + co investor Kindred Capital 2020-10-14
Oribiotech–Northpond Ventures: investment, 202010 financing round Series A totalling $30m incl new + lead investor Northpond Ventures 2020-10-14
Oribiotech–Octopus Ventures: investment, 202010 financing round Series A totalling $30m incl new + co-lead investor Octopus Ventures 2020-10-14
Oribiotech–SEVERAL: investment, 202010 financing round Series A $30m led by Northpond Ventures alongside Octopus Ventures 2020-10-14
Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink 2020-10-13
Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences 2020-10-13
Rappta Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital 2020-10-12
Priothera–Fountain Healthcare Partners: investment, 202010 financing round Series A totalling €30m incl lead investor FHP 2020-10-12
Priothera–Huntsworth: public relations, 202010 service existent by Citigate Dewe Rogerson 2020-10-12
Priothera–Kyorin: mocravimod, 202010c acquisition of mocravimod from Kyorin Pharmaceutical Co Ltd 2020-10-12
Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC 2020-10-12
Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group 2020-10-07
Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures 2020-10-07
GSK–Nvidia: AI-based drug discovery, 202010– collab with GSK AI Hub incl supply DGX A100 systems + Clara Discovery s/w + use Cambridge-1 supercomputer 2020-10-05
Sophia Genetics–Generation Investment Management: investment, 202010 financing round Series F totalling $110m incl existing + co-investor GIM 2020-10-01
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Venturse 2020-09-25
XenoGesis–Sygnature Discovery: investment, 202009 acquisition of XenoGesis by Sygnature Discovery 2020-09-24
Libra Therapeutics–Epidarex Capital: investment, 202009 financing round Series A totalling $29m incl co-lead investor Epidarex Capital 2020-09-23
Libra Therapeutics–SEVERAL: investment, 202009 financing round Series A $29m co-led by BIVF + Epidarex Capital + Santé 2020-09-23
ERS Genomics–Zyme Communications: public relations, 202009 service existent by Zyme 2020-09-22
Immune Regulation–24Haymarket: investment, 202009– financing round Series B totalling £40.6m incl existing + co-investor 24Haymarket 2020-09-21
Immune Regulation–Metellus: investment, 202009– financing round Series B totalling £40.6m incl co-investor Metellus AG 2020-09-21
Immune Regulation–Morningside: investment, 202009– financing round Series B totalling £40.6m incl new + lead investor Morningside Ventures 2020-09-21
Immune Regulation–SEVERAL: investment, 202009– financing round Series B £40.6m in two tranches + incl £6m advance subscription funds 2020-09-21
Inflazome–Byrne Wallace: legal services, 202009 supply service Byrne Wallace is legal advisor with regard to acquisition of Inflazome by Roche 2020-09-21
Inflazome–Goodwin Procter: legal services, 202009 supply service Goodwin Procter is legal advisor with regard to acquisition of Inflazome by Roche 2020-09-21
Inflazome–Lazard: financial services, 202009 supply service Lazard financial advisor with regard to acquisition of Inflazome by Roche 2020-09-21
Inflazome–Roche: investment, 202009 acquisition of Inflazome by Roche for €380m upfront + milestones 2020-09-21
Maetrics–Regulatory and Quality Solutions: investment, 202009 acquisition of Maetrics by R&Q 2020-09-16
Cellinta–Cancer Research UK: investment, 202009 seed financing round incl co-investor Cancer Research UK 2020-09-15
1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top